We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
In-vitro evaluation of Sen 34343: antimicrobial activity, β-lactamase stability and inhibition.
- Authors
Jones, Ronald N.; Barry, Arthur L.; Fuchs, Peter C.; Thornsberry, Clyde
- Abstract
Sch 34343 was compared with representative parenteral β-lactams including monobactams (aztreonam), I-oxa-β-lactams (latamoxef), carbapenems (imipenem) and cephalosporins (cefamandole, cefoperazone, cefotaxime, cefsulodin and ceftazidime). Sch 34343 was active against the Enterobacteriaceae (MIC50 range, 0.12–4.0 mg/1) and the facultative Gram-positive cocci (MIC50 range, 0.03–4.0 mg/1), and was comparable to the third-generation cephalosporins and imipenem. Pseudomonas aeruginosa and other Pseudomonas spp. were not susceptible to Sch 34343. Haemophilus influenzae and Neisseria spp. were all susceptible to ≤ 2.0 mg/1 of Sch 34343. Methicillin-resistant staphylococci (MIC90, 32 mg/1) appear to be insusceptible to Sch 34343.Sch 34343 inhibited the majority of cefotaxime- and gentamicin-resistant bacteria (MICs ≤ 8.0 mg/1). The new penem was stable to hydrolysis by 11 β-lactamase preparations (both plasmid- and chromosomsally-mcdiatcd types). Sch 34343 inhibited β-lactamases as did other newer cephalosporins.
- Publication
Journal of Antimicrobial Chemotherapy (JAC), 1985, Vol 15, Issue suppl_C, p99
- ISSN
0305-7453
- Publication type
Article